Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : neog - Neogen's E.Coli Test adopted by Japan -- Ignore unavailable to you. Want to Upgrade?

To: Rich H who wrote (360)	9/10/1999 11:02:00 PM
From: Kramer	Respond to of 441

RE /email to the analyst/ I'm not for sure who it is? It talked to a Roney guy a while back who seemed to be saying that they are not paying very close attention to neog these days; I suppose it could be theirs, but made a long time ago. The only other company I know that is covering neog is Hillard Lyons and they have a very thorough and accurate report on neog and I doubt very much that they would be off that much; besides I don't remember seeing that they have a quarterly estimate on neog. (I'd like to meet the Hillard Lyons analyst, because they are right on with their information and BTW they have a buy rating on neog).

To: Rich H who wrote (360)	9/16/1999 10:28:00 AM
From: Kramer	Read Replies (1) \| Respond to of 441

re /analyst estimates/ I did some checking around and the two companies, Roney & Hillard Lyons, that are covering neog have not posted estimates for this quarter. Roney & Hillard Lyons only have year end estimates for neog. First Call's information is correct as they do not have an estimate posted for this quarter. However, Zacks appears to have a phantom estimate out there for 16 cents for this quarter, which as I mentioned earlier IMO has no basis. BTW, neog will announce earnings September 30th.